BenzingaBenzinga Japan
BenzingaBenzinga Japan
BenzingaBenzinga Japan
水曜日, 9 30

Oruka Therapeutics Inc

ORKANASDAQ
Trade with Public
Trade with Public
$82.15
-2.04-2.42%
近くで: Sep 29, 5:00 PM EST
$81.00
-1.15-1.4%
時間外: 5:24 PM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成配当比較オプション株式レポート

Oruka Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Oruka Therapeutics (ORKA).

Price Target Range — 9 Quarters

Analyst Consensus — 15 Analysts

15Buy
Consensus RatingBuy# Analysts15Avg. Consensus PT$87Upside to Avg. PT+7.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →
DateFirmAnalystActionRating ChangePrice Target
Sep 24, 2026WedbushMartin Fan MaintainedOutperform$165
Sep 24, 2026HC Wainwright & Co.Mitchell S. KapoorMaintainedBuy$120
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target

Wedbush analyst Martin Fan reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and maintains $165 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
Benzinga Newsdesk

PRO
Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target

Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $200 price target.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target

BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $151 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

BenzingaBenzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved